QIAGEN emphasizes its global commitment to preventive screening, treatment of latent TB infection


QIAGEN NV (NYSE: QGEN; Frankfurt's premier standard: QIA) acknowledged the annual World Tuberculosis Day 2019, which took place on March 24, with an emphasis on the growing global commitment to preventive screening and treatment of latent tuberculosis (TB) infection. active tuberculosis in vulnerable patients.

QIAGEN is investing in a number of areas in terms of ease of use, flowability, efficiency of review, and the availability of tests for QuantiFERON-TB worldwide:

  • At the end of 2018, QIAGEN and DiaSorin introduced a CE-marked reading kit for QuantiFERON-TB Gold Plus for use on DiaSorin's widely used LIAISON platforms. The introduction of QFT-Plus as part of a comprehensive list of DiaSorin tests on more than 7,000 LIAISON instruments in hospitals and laboratories around the world adds an effective automated solution to TB screening programs. The availability of QFT-Plus reading kits for use on LIAISON platforms is expected in 2019 in the US and in 2020 in China.
  • QIAGEN has been working with Hamilton Robotics and Tecan for single pipe solutions that offer highly efficient automation of pre-analytical processing operations.
  • At the beginning of 2019, QIAGEN announced plans to develop a new and proprietary QuantiFERON-TB Access (QFT® Access) solution designed and adapted to the needs of low-consumption regions with a high TB ​​illness. QFT Access is designed to combine ultra-sensitive digital detection of latent TB infection with a complete workflow, created with a focus on cost-effectiveness and ease of use. QIAGEN develops QFT Access in a new partnership with Ellume, an Australian developer of digitally-enabled diagnostics. Clinical trials for QFT access are expected to begin in 2019, and commercialization is expected to begin in 2020.




Source link